Bone Metastases in Metastatic Renal Cell Carcinoma: Now We Know That Cabozantinib Targets Bone Microenvironment

The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) in the METEOR trial, a phase III, randomized, open-label trial [1,2], leading to its approval in mRCC patients previously treated with antiangiogenic agents.

Author(s): Raffaele Ratta, Daniele Santini, Elena Verzoni and Giuseppe Procopio

Abstract | Full-Text | PDF

Share This Article